Hydrogen Capsules Help Woman with Lupus Heart Condition
Molecular Hydrogen Therapy for SLE-PAH: Case Report on Immune Marker Modulation
Research hubs: Cardiovascular System · Respiratory System
- Evidence type
- Case report or series · Human study
- Authors
- TING-HAO TU, JENG-WEI LU, CHUN-HSIEN WU, YI-JUNG HO, SHAN-WEN LUI, TING-YU HSIEH, KUANG-YIH WANG, FENG-CHENG LIU
- Journal
- In Vivo
- Year
- 2025
- PMID
- 40010970
- Study Type
- Human
- Participants
- 1
- Delivery
- Gas
- Dose
- daily hydrogen capsules
- Funding
- Ministry of Science and Technology (MOST 111-2314-B-016-026); National Science and Technology Council (NSTC 112-2314-B-016-033); National Science and Technology Council (NSTC 113-2314-B-016-052); Tri-Service General Hospital (TSGH-E-111215); Tri-Service General Hospital (TSGH-E-112218)
- Conflicts of interest
- None declared
- Outcome
- Positive
- Peer Reviewed
- Yes
- Cited by
- 4 (OpenAlex, as of November 2026)
- Country
- Taiwan
TL;DR
Breathing in molecular hydrogen helped improve the symptoms of a patient with a severe heart and lung complication from lupus, without causing any side effects.
Key Finding
A single patient with severe SLE-PAH showed symptom stabilization and changes in immune markers (increased Tr1 cells, decreased Treg and B cells) after receiving daily hydrogen capsules as an add-on treatment.
Summary
This report describes one patient with a serious lung condition called SLE-PAH (a complication of lupus that causes high blood pressure in the lungs) who was given hydrogen capsules as an additional treatment alongside her regular medications. After starting hydrogen therapy, her symptoms stabilized and her immune system markers changed in ways that suggested reduced inflammation, with no harmful side effects observed.
Practical Takeaway
While this case report suggests hydrogen therapy was well-tolerated and may have supported immune changes in one patient with a severe autoimmune lung condition, it represents only a single case. Much larger studies are needed before any conclusions can be drawn about whether hydrogen therapy could help people with SLE-PAH. Anyone with this condition should discuss any new treatments with their doctor.
Abstract (excerpt)
Background/aim: Systemic lupus erythematosus-associated pulmonary arterial hypertension (SLE-PAH) is a severe complication marked by elevated pulmonary artery pressure, leading to exertional dyspnea and right-sided heart failure. Standard treatments frequently fall short in effectively controlling…